Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423)

Short CommunicationVolume 5 Issue 3

Novel Nanocarrier based Drug Delivery Systems for Cancer Therapy

Om Prakash Ranjan*

Assistant Professor, Faculty of Pharmacy, Sachchidanand Sinha College, Aurangabad, Bihar, India

*Corresponding Author: Om Prakash Ranjan, Assistant Professor, Faculty of Pharmacy, Sachchidanand Sinha College, Aurangabad, Bihar, India.

Received: February 13, 2021; Published: February 25, 2021

Citation: Om Prakash Ranjan. “Novel Nanocarrier based Drug Delivery Systems for Cancer Therapy”. Acta Scientific Pharmaceutical Sciences 5.3 (2021): 37-38.

  Cancer is one of the leading causes of death worldwide. Despite efforts to alleviate risk factors in recent decades, the incidence of cancer is continuing to increase [1]. As cancer cells grow faster than healthy ones, fast-growing cells are the main targets of chemotherapeutics. The limitations of conventional chemotherapy have led to the development of nanocarrier-based drug delivery systems which target drugs to specific sites [2]. Nanocarriers can improve drug efficacy and selectivity through enhanced permeability and retention (EPR) effects in tumor cells. Among the nanocarriers, liposomes, polymeric nanoparticles, and micelles have received the most attention. So far, numerous nanoparticle-based chemotherapeutics are clinically approved whilst others are in the advanced stages of clinical development [3]. Depending on the sorts and applications of nanocarriers, there are a few steps to convert ordinary nanocarriers into novel and particular. First, nanocarriers face many biological barriers, including cleansing by the reticuloendothelial system (RES) on the way to the targeted site. PEGylation is a unique technique to avoid this cleansing process and it help nanocarriers to escape the RES. Second, nanocarriers can be functionalized to identify the cancer cells precisely out of healthy ones. The surface of cancer cells over expresses some proteins. Nanocarriers are modified with ligands matching the over expressed proteins. The ligands of nanocarriers identify the cells with the receptor proteins [2].

  A liposome is a spherical-shaped vesicle that is composed of one or more phospholipid bilayers, which closely resembles the structure of cell membranes. The ability of liposomes to encapsulate hydrophilic or lipophilic drugs has allowed these vesicles to become useful drug delivery systems. Liposomes have been considered to be the most successful nanocarriers for drug deliver and have made their way to the market. Liposomes overcome the limitations of conventional chemotherapy by improving the bioavailability and stability of the drug molecules and minimizing side effects by site-specific targeted delivery of the drugs. Doxil (US) or Caelyx (outside-US) is a PEGylated liposomal formulation encapsulating anticancer drug doxorubicin commercialized by Johnson and Johnson. LipoDox is the same liposomal formulation as Doxil in USA and made in India by Sun Pharma and in 2013, FDA approved the first generic version of Doxil, made by Sun Pharma [4]. Polymeric nanoparticles (NPs) are particles within the size range from 1 to 1000 nm and can be loaded with active compounds entrapped within or surface-adsorbed onto the polymeric core [2]. The polymeric drug-loaded nanoparticles have been viewed as a novel promising strategy for cancer treatment because they not only can improve the drug pharmacokinetics but also further response to the permeation and retention (EPR) effect to enhance the accumulation of drugs at the site of the tumor during cancer treatment. The recent research hotspot of polymers utilized for drug loaded nanoparticles include poly (D, L-lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), poly (ethylene glycol) (PEG), chitosan (CS), and hyaluronic acid (HA), etc [5].


  1. PN Navya., et al. “Current trends and challenges in cancer management and therapy using designer nanomaterials”. Nano Convergence 6 (2019): 23.
  2. Sarwar Hossen M., et al. “Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review”. Journal of Advanced Research 15 (2019): 1-18.
  3. Ke-Tao Jin., et al. “Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment”. Journal of Nanomaterials (2020): 14.
  4. Himanshu Pandey., et al. “Liposome and Their Applications in Cancer Therapy”. Brazilian Archives of Biology and Technology 59 (2016): e16150477.
  5. Binbin Li., et al. “Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting”. Frontiers in Pharmacology (2017).

Copyright: © 2021 Om Prakash Ranjan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US